The treatment of disc herniation-induced sciatica with infliximab : One-year follow-up results of FIRST II, a randomized controlled trial

A randomized controlled trial. To evaluate the long-term efficacy of infliximab, a monoclonal antibody against tumor necrosis factor alpha (TNF-alpha), in patients with acute/subacute sciatica secondary to herniated disc. The results of experimental studies and our open-label trial support the use o...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Spine (Philadelphia, Pa. 1976) Pa. 1976), 2006-11, Vol.31 (24), p.2759-2766
Hauptverfasser:	KORHONEN, Timo, KARPPINEN, Jaro, VEEGER, Nic, HAAPEA, Marianne, TORKKI, Markus, TERVONEN, Osmo, SEITSALO, Seppo, HURRI, Heikki, PAIMELA, Leena, MALMIVAARA, Antti, LINDGREN, Karl-August, BOWMAN, Chris, HAMMOND, Anthony, KIRKHAM, Bruce, JÄRVINEN, Simo, NIINIMÄKI, Jaakko
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute Disease Adult Anti-Inflammatory Agents - adverse effects Anti-Inflammatory Agents - therapeutic use Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Biological and medical sciences Cerebrospinal fluid. Meninges. Spinal cord Disease Susceptibility Diskectomy Drug toxicity and drugs side effects treatment Female Follow-Up Studies Hospitalization - statistics & numerical data Humans Immunomodulators Infection - etiology Infliximab Intervertebral Disc Displacement - complications Intervertebral Disc Displacement - drug therapy Lumbar Vertebrae Male Medical sciences Middle Aged Nervous system (semeiology, syndromes) Neurology Pain Measurement Pharmacology. Drug treatments Quality of Life Recovery of Function Sciatica - drug therapy Sciatica - etiology Subacute Care Toxicity: nervous system and muscle Treatment Outcome Tumor Necrosis Factor-alpha - antagonists & inhibitors Tumor Necrosis Factor-alpha - physiology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!